Clinical Report: The Use of Tocilizumab in Treating Pediatric FIRES

Overview

This report discusses the therapeutic effects of tocilizumab in two pediatric patients with Febrile Infection-Related Epilepsy Syndrome (FIRES). Early administration of tocilizumab appears to correlate with improved seizure outcomes, particularly when given within three weeks of disease onset.

Background

Febrile Infection-Related Epilepsy Syndrome (FIRES) is a severe condition characterized by super refractory status epilepticus in previously healthy children following a febrile illness. The management of FIRES is challenging, often yielding unsatisfactory results with conventional therapies. Recent insights into the role of cytokines in FIRES suggest that targeting the immune response may offer new therapeutic avenues.

Data Highlights

Key Findings

• Patient 1 received tocilizumab on day 58 with transient seizure relief.
• Patient 2 received tocilizumab on day 7 and experienced no seizures during follow-up.
• Elevated IL-6 levels were noted in both patients' blood samples.
• Clinical symptoms included focal seizures and status epilepticus.
• Seven pediatric FIRES cases treated with tocilizumab have been reported to date.
• Early administration of tocilizumab may improve treatment outcomes in FIRES.

Clinical Implications

Clinicians should consider early administration of tocilizumab in pediatric patients diagnosed with FIRES, particularly within three weeks of symptom onset. Monitoring for IL-6 levels may guide treatment decisions and timing.

Conclusion

The findings suggest that tocilizumab may be a beneficial treatment option for pediatric FIRES, especially when administered early in the disease course. Further studies are warranted to establish optimal treatment protocols.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Model-informed safety management of tocilizumab for pediatric sJIA
2. Clinical Rheumatology, 2024 -- Assessment of the safety and effectiveness of tocilizumab in Chinese individuals with sJIA
3. Frontiers in Immunology, 2026 -- Clinical application of HMGB1-TLR4 signaling pathway-mediated neuroinflammatory markers in infantile epileptic spasms syndrome
4. International consensus recommendations for management of New Onset Refractory Status Epilepticus (NORSE) including FIRES
5. Tocilizumab for super-refractory status epilepticus in children with FIRES: A case series
6. Frontiers in Pediatrics — Intubation in children presenting with seizures to a pediatric emergency department in a safety net hospital
7. NIH PMC - International consensus recommendations for management of NORSE
8. Tocilizumab for super-refractory status epilepticus in children with FIRES: A case series - ScienceDirect
9. Comparing the Effects of Anakinra and Tocilizumab on Outcomes in Patients With New-Onset Refractory Status Epilepticus | PCORI